Last reviewed · How we verify
Aerosol foam vehicle
An aerosol foam vehicle formulation designed to deliver active pharmaceutical ingredients topically to affected skin areas with improved coverage and adherence.
An aerosol foam vehicle formulation designed to deliver active pharmaceutical ingredients topically to affected skin areas with improved coverage and adherence. Used for Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulated with this vehicle).
At a glance
| Generic name | Aerosol foam vehicle |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Aerosol foam vehicles are pharmaceutical delivery systems that dispense active ingredients in a lightweight foam format, allowing for easier application to large body surface areas and better penetration into affected skin. The foam formulation enhances drug deposition and patient compliance compared to traditional topical formulations. LEO Pharma's aerosol foam vehicle is a platform technology used to optimize delivery of various dermatological agents.
Approved indications
- Dermatological conditions requiring topical treatment (specific indication dependent on active ingredient formulated with this vehicle)
Common side effects
- Local skin irritation
- Contact dermatitis
- Application site reactions
Key clinical trials
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis (PHASE3)
- A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis (PHASE3)
- Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) (PHASE3)
- LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (PHASE2)
- A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aerosol foam vehicle CI brief — competitive landscape report
- Aerosol foam vehicle updates RSS · CI watch RSS
- LEO Pharma portfolio CI